Schizophrenia Relapse Reduction Program

As part of our dedication to providing you leading insights in schizophrenia, Otsuka Pharmaceutical Development & Commercialization, Inc. is pleased to offer the Frameworks in Health and Quality: Schizophrenia Relapse Reduction Program.

Schizophrenia is a chronic, relapsing, and disabling disorder characterized by symptoms such as hallucinations and delusions, disorganized thinking, affective flattening, apathy, and social withdrawal. Schizophrenia is characterized by recurrent episodes of relapse of psychotic symptoms. The risk of relapse is great, with the 1-year rate as high as 50% and the 5-year rate as high as 80%. Prevention of relapse is one crucial goal of long-term therapy in schizophrenia.

This program is a set of unbranded resources for health care stakeholders—payers, providers, patients, and caregivers. The program aims to support emerging clinical market dynamics and opportunities as they relate to schizophrenia relapse reduction.

Program objectives:

  • Assist and complement relapse reduction efforts
  • Enhance communication among all stakeholders
  • Provide stakeholders with relapse educational materials for patients and caregivers
  • Emphasize patient wellness and adherence to treatment plans
  • Promote other important relapse reduction topics such as medication reconciliation, transitions of care, and quality measures

This disease management program supports:

Payers

Program introductory materials and key issues for payers including HEDIS" quality improvement guidance resources and disease management program components

Click here to view these resources.

Health Care Providers

Program introductory materials and education and awareness resources for providers, community mental health centers, case managers, hospital treatment teams, social workers and other patient advocates; including relapse and disease management, adherence, and medication reconciliation resources

Click here to view these resources.

Patients and Caregivers

Schizophrenia and relapse education and awareness resources that also include tools for relapse action planning, adherence, and hospitalization resources, all of which are available in Spanish.

Click here to view these resources.

Relapse Reduction and Schizophrenia

Because relapse in schizophrenia is associated with a heavy financial and human burden, its reduction has become an important goal. Implementation of disease management strategies may help improve care coordination, relapse reduction, and clinical outcomes for patients with schizophrenia.

These resources are provided for informational purposes only and are not intended as reimbursement or legal advice. You should seek independent, qualified professional advice to ensure that your organization is in compliance with the complex legal and regulatory requirements governing health care services and that treatment decisions are made consistent with the applicable standards of care.